AliveCor, Inc.

AliveCor, Inc. is a pioneering healthcare technology company specializing in portable ECG devices, providing innovative solutions for heart health monitoring and management. Founded in 2010 in Mountain View, US, AliveCor focuses on producing advanced cardiological care products. The company has undergone significant growth since its inception and operates independently.

AliveCor was co-founded by Bruce Satchwell, Christan Hiscock, David Albert, Heather Gardner, JO OJ, and Kim Barnett. As of the latest funding round in August 2022, AliveCor raised USD 56. 235 mn in Series E funding with participation from notable investors including BOLD Capital Partners and Khosla Ventures, bringing its total amount raised to USD 56. 235 mn and a current company valuation of USD 467.

193 mn. AliveCor specializes in advanced cardiological care through its innovative products and services, focusing on portable electrocardiogram (ECG) technology. The flagship product, the Kardia 12L, is the first portable 12-lead ECG, designed for both healthcare professionals and patients. The KardiaMobile 6L and KardiaStation enable users to capture medical-grade heart data remotely, facilitating continuous monitoring for heart health management.

Their solutions cater to individual consumers, healthcare providers, biopharma companies, and health systems, addressing the critical need for accessible heart health monitoring across regions including the United States, Canada, and countries in Europe, Asia, and Latin America. AliveCor generates revenue through direct sales and subscription models associated with its ECG devices and services. Healthcare professionals and consumers purchase products like the KardiaMobile and Kardia 12L, often alongside subscription-based access to data management and telehealth services. The pricing structure includes one-time device purchases and ongoing fees for services supporting cardiac health monitoring.

Partnerships with healthcare providers and biopharma companies enhance revenue by integrating technology into clinical workflows and research. To support its growth strategy, AliveCor plans to utilize the funds raised in August 2022 to advance its cardiological care subscription services and accelerate its expansion into new strategic markets. This includes targeting specific regions for expansion, although dates for these efforts have not been disclosed. The company aims to introduce new products designed to enhance its service offerings, further establishing its presence in the health tech industry.